AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27209586 — intervention group
Group type: EXPERIMENTAL
Intervention: CHF 5993 with cimetidine (800 mg twice daily for 6 days)
Number of subjects: 26
Study 27209586 — intervention group
Group type: EXPERIMENTAL
Intervention: CHF 5993 with cimetidine
Number of subjects: 26
Study 27209586 — intervention group
Group type: COMPARATOR
Intervention: CHF 5993 alone
Number of subjects: 26
Study 25998033 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard oxygen therapy
Number of subjects: 100
Study 25998033 — intervention group
Group type: COMPARATOR
Intervention: No supplemental oxygen
Number of subjects: 100
Study 23857809 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized cognitive rehabilitation (Cog‐trainer) plus usual rehabilitation (UR)
Number of subjects: 60
Study 23857809 — intervention group
Group type: COMPARATOR
Intervention: Usual rehabilitation (UR)
Number of subjects: 60
Study 21723220 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 0
Study 21723220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19735529 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 0
Study 19735529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16293673 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention to resume smoking (IRS)
Number of subjects: 301
Study 16293673 — intervention group
Group type: COMPARATOR
Intervention: No intention to resume smoking (no IRS)
Number of subjects: 301
Study 16293673 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of months currently abstinent
Number of subjects: 301
Study 15321433 — intervention group
Group type: EXPERIMENTAL
Intervention: VT x 3 min
Number of subjects: 20
Study 15321433 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 DB
Number of subjects: 20
Study 15321433 — intervention group
Group type: COMPARATOR
Intervention: 4 DB
Number of subjects: 20
Study 11766956 — intervention group
Group type: EXPERIMENTAL
Intervention: Home physiotherapy program, 3 times a week for 6 weeks
Number of subjects: 33
Study 9028089 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrinone (3-5 mg.kg-1.min-1) combined with dopamine (3-5 mg.kg-1.min-1)
Number of subjects: 9
Study 9028089 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin (0.3-1.0 mg.kg-1.min-1) combined with dopamine (3-5 mg.kg-1.min-1)
Number of subjects: 9
Study 8500234 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal therapy in patients < 75 years old
Number of subjects: 1000
Study 8500234 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 1000
Study 2952156 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical clindamycin phosphate 1%
Number of subjects: 60
Study 2952156 — intervention group
Group type: COMPARATOR
Intervention: Oral tetracycline
Number of subjects: 60
Study 29110281 — intervention group
Group type: EXPERIMENTAL
Intervention: weight-loss intervention + 50,000 IU/week oral vitamin D3
Number of subjects: 60
Study 29110281 — intervention group
Group type: COMPARATOR
Intervention: weight-loss intervention + placebo
Number of subjects: 60
Study 27930479 — intervention group
Group type: EXPERIMENTAL
Intervention: Career management intervention
Number of subjects: 684
Study 27930479 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 684
Study 24703512 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial release (MFR)
Number of subjects: 66
Study 24703512 — intervention group
Group type: COMPARATOR
Intervention: Sham ultrasound therapy (SUST)
Number of subjects: 66
Study 23677313 — intervention group
Group type: EXPERIMENTAL
Intervention: Burch urethropexy
Number of subjects: 233
Study 23677313 — intervention group
Group type: COMPARATOR
Intervention: No urethropexy
Number of subjects: 233
Study 23677313 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 233
Study 19865092 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg atorvastatin daily for 12 weeks
Number of subjects: 131
Study 19865092 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo for 12 weeks
Number of subjects: 131
Study 18262390 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat test meal (59 +/- 4 g fat; 71% of energy as fat) with high saturated:unsaturated fatty acids ratio (approximately 71:29)
Number of subjects: 18
Study 18262390 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat test meal (59 +/- 4 g fat; 71% of energy as fat) with low saturated:unsaturated fatty acids ratio (approximately 55:45)
Number of subjects: 18
Study 16169354 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin-sensitive patients
Number of subjects: 117
Study 16169354 — intervention group
Group type: COMPARATOR
Intervention: Aspirin-resistant patients
Number of subjects: 117
Study 12663284 — intervention group
Group type: EXPERIMENTAL
Intervention: L-amino acid diet supplying either 14 and 30 mg leucine x kg(‐1)x d(‐1) or 22 and 40 mg leucine x kg(‐1)x d(‐1)
Number of subjects: 26
Study 12663284 — intervention group
Group type: COMPARATOR
Intervention: Habitual cereal-and-lentil-based diets
Number of subjects: 26
Study 12663284 — intervention group
Group type: EXPERIMENTAL
Intervention: [2H3]leucine administered orally at an intake of 40 mg x kg(‐1) x d(‐1)
Number of subjects: 26
Study 10638903 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium infusion at 5 microg x kg(‐1) x min(‐1) until the first response of each train‐of‐four had decreased by 70%.
Number of subjects: 12
Study 10638903 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium infusion at 20 microg x kg(‐1) x min(‐1) for 10 min.
Number of subjects: 12
Study 8799921 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cyst excision
Number of subjects: 131
Study 8799921 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic cyst aspiration
Number of subjects: 131
Study 1320538 — intervention group
Group type: EXPERIMENTAL
Intervention: High-voltage pulsed galvanic stimulation at 2 pulses/s
Number of subjects: 12
Study 1320538 — intervention group
Group type: EXPERIMENTAL
Intervention: High-voltage pulsed galvanic stimulation at 128 pulses/s
Number of subjects: 12
Study 1320538 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric contraction of calf muscles
Number of subjects: 12
Study 1320538 — intervention group
Group type: EXPERIMENTAL
Intervention: High-voltage pulsed galvanic stimulation at 32 pulses/s
Number of subjects: 12
Study 6529613 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg xipamide
Number of subjects: 13
Study 6529613 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg xipamide
Number of subjects: 13
Study 6529613 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg xipamide
Number of subjects: 13
Study 6529613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 30449747 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention interns (home visitation)
Number of subjects: 52
Study 26501497 — intervention group
Group type: EXPERIMENTAL
Intervention: Relationship education intervention
Number of subjects: 1034
Study 26501497 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 1034
Study 24387700 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 84
Study 24387700 — intervention group
Group type: COMPARATOR
Intervention: Active Control (nonaerobic exercise)
Number of subjects: 84
Study 24387700 — intervention group
Group type: COMPARATOR
Intervention: Yoga vs Active Control
Number of subjects: 84
Study 22561416 — intervention group
Group type: EXPERIMENTAL
Intervention: Sauna-only sessions (S)
Number of subjects: 10
Study 22561416 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise followed by sauna sessions (ES)
Number of subjects: 10
Study 22561416 — intervention group
Group type: COMPARATOR
Intervention: Control resting session
Number of subjects: 10
Study 20337866 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mL tea
Number of subjects: 12
Study 20337866 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mL tea
Number of subjects: 12
Study 20337866 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL tea
Number of subjects: 12
Study 18420395 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean fish (3 x 150 g portions of cod/week)
Number of subjects: 275
Study 18420395 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty fish (3 x 150 g portions of salmon/week)
Number of subjects: 275
Study 18420395 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (DHA+EPA capsules, no seafood)
Number of subjects: 275
Study 18420395 — intervention group
Group type: COMPARATOR
Intervention: Control (sunflower oil capsules, no seafood)
Number of subjects: 275
Study 16110022 — intervention group
Group type: EXPERIMENTAL
Intervention: TP53 mutation
Number of subjects: 391
Study 16110022 — intervention group
Group type: EXPERIMENTAL
Intervention: MSI-H
Number of subjects: 391
Study 16110022 — intervention group
Group type: EXPERIMENTAL
Intervention: KRAS mutations
Number of subjects: 391
Study 12852722 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict fasting capillary glucose target level (< 6.5 mmol/l)
Number of subjects: 214
Study 12852722 — intervention group
Group type: COMPARATOR
Intervention: Less strict fasting capillary glucose target level (< 8.5 mmol/l)
Number of subjects: 214
Study 12852722 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall group (no specific intervention)
Number of subjects: 214
Study 10681104 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 63
Study 10681104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 10681104 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (non-volunteers)
Number of subjects: 63
Study 8596231 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained service dogs (received 1 month after the study began)
Number of subjects: 48
Study 8596231 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (received service dogs in month 13 of the study)
Number of subjects: 48
Study 8596231 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained service dogs
Number of subjects: 48
Study 2015447 — intervention group
Group type: EXPERIMENTAL
Intervention: Day care treatment
Number of subjects: 92
Study 2015447 — intervention group
Group type: COMPARATOR
Intervention: Out-patient care
Number of subjects: 92
Study 6781618 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy
Number of subjects: 82
Study 6781618 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 82
Study 6781618 — intervention group
Group type: COMPARATOR
Intervention: Initial platelet counts
Number of subjects: 82
Study 6781618 — intervention group
Group type: COMPARATOR
Intervention: Age
Number of subjects: 82
Study 6781618 — intervention group
Group type: COMPARATOR
Intervention: Total white cell count
Number of subjects: 82
Study 6781618 — intervention group
Group type: COMPARATOR
Intervention: Granulocyte counts
Number of subjects: 82
Study 6781618 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse rates
Number of subjects: 82
Study 6781618 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival after five years
Number of subjects: 82
Study 31194759 — intervention group
Group type: EXPERIMENTAL
Intervention: %HRR-CV during cardiovascular training
Number of subjects: 30
Study 31194759 — intervention group
Group type: EXPERIMENTAL
Intervention: %HRR-AR during active recovery phases
Number of subjects: 30
Study 31194759 — intervention group
Group type: COMPARATOR
Intervention: Comparison of %HRR-CV with 40% HRR threshold
Number of subjects: 30
Study 31194759 — intervention group
Group type: COMPARATOR
Intervention: Comparison of %HRR-AR and %HRR-CV
Number of subjects: 30
Study 28412163 — intervention group
Group type: EXPERIMENTAL
Intervention: Tail docking using clippers in 2-day-old pigs
Number of subjects: 40
Study 28412163 — intervention group
Group type: EXPERIMENTAL
Intervention: Tail docking using clippers in 20-day-old pigs
Number of subjects: 40
Study 28412163 — intervention group
Group type: EXPERIMENTAL
Intervention: Tail docking using cautery iron in 20-day-old pigs
Number of subjects: 40
Study 28412163 — intervention group
Group type: EXPERIMENTAL
Intervention: Tail docking using clippers or cautery iron in 2-day-old pigs
Number of subjects: 40
Study 28412163 — intervention group
Group type: EXPERIMENTAL
Intervention: Tail docking in 2-day-old pigs
Number of subjects: 40
Study 28412163 — intervention group
Group type: EXPERIMENTAL
Intervention: Tail docking in 20-day-old pigs
Number of subjects: 40
Study 26321155 — intervention group
Group type: EXPERIMENTAL
Intervention: P10 (chemical-cured resin composite)
Number of subjects: 30
Study 26321155 — intervention group
Group type: EXPERIMENTAL
Intervention: P30 (light-cured resin composite)
Number of subjects: 30
Study 26321155 — intervention group
Group type: EXPERIMENTAL
Intervention: Miradapt (chemical-cured resin composite)
Number of subjects: 30
Study 26321155 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 30
Study 23442174 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasonography (CEUS) during LRFA
Number of subjects: 96
Study 23442174 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CEUS)
Number of subjects: 96
Study 23442174 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 96
Study 21204871 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus NCFM
Number of subjects: 50
Study 21204871 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis Bi-07
Number of subjects: 50
Study 21204871 — intervention group
Group type: COMPARATOR
Intervention: Probiotic intake
Number of subjects: 50
Study 19650825 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD9343 320 mg
Number of subjects: 27
Study 19650825 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen 40 mg
Number of subjects: 27
Study 19650825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 17239705 — intervention group
Group type: EXPERIMENTAL
Intervention: Istaroxime at doses >or=1 micro/kg per min
Number of subjects: 18
Study 17239705 — intervention group
Group type: EXPERIMENTAL
Intervention: Istaroxime at doses of 0.5 micro/kg per min
Number of subjects: 18
Study 17239705 — intervention group
Group type: EXPERIMENTAL
Intervention: Istaroxime
Number of subjects: 18
Study 17239705 — intervention group
Group type: EXPERIMENTAL
Intervention: Istaroxime up to 3.33 micro/kg per min
Number of subjects: 18
Study 15078001 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem 1 g daily
Number of subjects: 236
Study 15078001 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin-tazobactam 3.375 g every 6 h
Number of subjects: 236
Study 15078001 — intervention group
Group type: EXPERIMENTAL
Intervention: Complicated appendicitis
Number of subjects: 236
Study 15078001 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 236
Study 14642996 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) at a mean dose of 2053 mg/day for a duration of 125 days
Number of subjects: 970
Study 14642996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 970
Study 10451131 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg tramadol
Number of subjects: 60
Study 10451131 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg tramadol
Number of subjects: 60
Study 10451131 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control group)
Number of subjects: 60
Study 7851201 — intervention group
Group type: EXPERIMENTAL
Intervention: Bran (20 g/24 hr)
Number of subjects: 24
Study 7851201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2108510 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate
Number of subjects: 28
Study 2108510 — intervention group
Group type: COMPARATOR
Intervention: Oxygen therapy alone
Number of subjects: 28
Study 7465712 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent Feedback
Number of subjects: 18
Study 7465712 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback plus Exteroceptive Cues
Number of subjects: 18
Study 7465712 — intervention group
Group type: COMPARATOR
Intervention: Random Feedback Control
Number of subjects: 18
Study 31465818 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin infiltration + flossing (test group)
Number of subjects: 50
Study 31465818 — intervention group
Group type: COMPARATOR
Intervention: Flossing (control group)
Number of subjects: 50
Study 27567635 — intervention group
Group type: EXPERIMENTAL
Intervention: NOVOCART® Disk plus (autologous disk chondrocyte transplantation)
Number of subjects: 24
Study 27567635 — intervention group
Group type: COMPARATOR
Intervention: Carrier material only (control)
Number of subjects: 24
Study 27567635 — intervention group
Group type: EXPERIMENTAL
Intervention: NOVOCART® Disk plus
Number of subjects: 24
Study 25437877 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month semi-supervised moderate exercise protocol (EX, n = 66)
Number of subjects: 128
Study 25437877 — intervention group
Group type: COMPARATOR
Intervention: Health education control (CON, n = 62)
Number of subjects: 128
Study 23497557 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 40
Study 23497557 — intervention group
Group type: COMPARATOR
Intervention: Oxygen mask (OM)
Number of subjects: 40
Study 22131599 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (n = 27)
Number of subjects: 43
Study 22131599 — intervention group
Group type: COMPARATOR
Intervention: Stretching control (n = 16)
Number of subjects: 43
Study 19607686 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training home exercise programme from a physiotherapist
Number of subjects: 214
Study 19607686 — intervention group
Group type: COMPARATOR
Intervention: Education, information and support programme from an occupational therapist
Number of subjects: 214
Study 18000962 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronicle ICD group (hemodynamic monitoring system)
Number of subjects: 850
Study 18000962 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care without hemodynamic monitoring)
Number of subjects: 850
Study 15521899 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg salbutamol via pMDI + Volumatic
Number of subjects: 18
Study 15521899 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg salbutamol via pMDI + Volumatic
Number of subjects: 18
Study 15521899 — intervention group
Group type: EXPERIMENTAL
Intervention: salbutamol via pMDI + Volumatic
Number of subjects: 18
Study 15521899 — intervention group
Group type: EXPERIMENTAL
Intervention: low dose salbutamol via pMDI + Volumatic
Number of subjects: 18
Study 15521899 — intervention group
Group type: EXPERIMENTAL
Intervention: high dose salbutamol via Diskus
Number of subjects: 18
Study 11134196 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (5 mg orally, four times a day)
Number of subjects: 201
Study 11134196 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide (250 mg orally, three times a day)
Number of subjects: 201
Study 9662678 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care, practice-based physical activity behavioral interventions
Number of subjects: 874
Study 9662678 — intervention group
Group type: COMPARATOR
Intervention: Standard care control condition
Number of subjects: 874
Study 31760401 — intervention group
Group type: EXPERIMENTAL
Intervention: SLK triple therapy
Number of subjects: 240
Study 28229548 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligofructose (21 g for 12 weeks)
Number of subjects: 37
Study 28229548 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 37
Study 26681629 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice (525 mg for days 1-3, 1050 mg for day 4)
Number of subjects: 18
Study 26681629 — intervention group
Group type: COMPARATOR
Intervention: Nitrate-depleted beetroot juice (PLACEBO)
Number of subjects: 18
Study 24338654 — intervention group
Group type: EXPERIMENTAL
Intervention: FLESHD (frequent low-efficiency and short hemodialysis)
Number of subjects: 13
Study 24338654 — intervention group
Group type: EXPERIMENTAL
Intervention: FLESHF (frequent low-efficiency and short hemofiltration)
Number of subjects: 13
Study 24338654 — intervention group
Group type: EXPERIMENTAL
Intervention: FLESHD
Number of subjects: 13
Study 24338654 — intervention group
Group type: EXPERIMENTAL
Intervention: FLESHF
Number of subjects: 13
Study 19726379 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg flurbiprofen axetil (group F)
Number of subjects: 60
Study 19726379 — intervention group
Group type: COMPARATOR
Intervention: 10 ml intravenous saline (group C)
Number of subjects: 60
Study 19726379 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 17600040 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular hypertrophy (LVH)
Number of subjects: 7443
Study 17600040 — intervention group
Group type: COMPARATOR
Intervention: No left ventricular hypertrophy (no LVH)
Number of subjects: 7443
Study 15152708 — intervention group
Group type: EXPERIMENTAL
Intervention: Chestnut Health System's best‐practice Outpatient Treatment (CHS)
Number of subjects: 274
Study 15152708 — intervention group
Group type: COMPARATOR
Intervention: Cannabis Youth Treatment (CYT)
Number of subjects: 274
Study 12473255 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 80 mg daily
Number of subjects: 540
Study 12473255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 540
Study 12473255 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin treatment
Number of subjects: 540
Study 12473255 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin treatment in patients with pronounced ischaemia
Number of subjects: 540
Study 9726529 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted prescription systems for anticoagulation management
Number of subjects: 1336
Study 9726529 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard anticoagulation management)
Number of subjects: 1336
Study 8612436 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal protein diet (APD) (protein intake 1.1 g · kg‐1 · day‐1)
Number of subjects: 9
Study 8612436 — intervention group
Group type: COMPARATOR
Intervention: Vegetable protein diet (VPD) (protein intake 0.95 g · kg‐1 · day‐1)
Number of subjects: 9
Study 2094145 — intervention group
Group type: EXPERIMENTAL
Intervention: 3mg PGE2 vaginal tablet
Number of subjects: 24
Study 2094145 — intervention group
Group type: EXPERIMENTAL
Intervention: 1mg PGE2 vaginal gel
Number of subjects: 24